Presentation is loading. Please wait.

Presentation is loading. Please wait.

Performance characteristics for multivariate assay SLE panel.

Published byErwin Hofer Modified over 5 years ago

Similar presentations

Presentation on theme: "Performance characteristics for multivariate assay SLE panel."— Presentation transcript:

1 Performance characteristics for multivariate assay SLE panel.
Performance characteristics for multivariate assay SLE panel. The number of subjects in tier 1 and tier 2 (positive and negative) is indicated. Median index score (IQR) in tier 2 is provided. Overall diagnostic sensitivities (sens.) are provided for SLE. Specificities for other rheumatology diseases (spec.) are also given. NHV, normal healthy volunteers; SLE, systemic lupus erythematosus; PM/DM, polymyositis/dermatomyositis; RA, rheumatoid arthritis. Chaim Putterman et al. Lupus Sci Med 2014;1:e000056 ©2014 by Lupus Foundation of America

Download ppt "Performance characteristics for multivariate assay SLE panel."

Similar presentations

From: Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease Ann Intern Med. 1997;126(11):866-873.

From: Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease Ann Intern Med. 1997;126(11):
Figure 1 Historical evolution of the clinical classification and

Figure 1 Historical evolution of the clinical classification and
Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.
Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.

Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.
Figure 3 Transcriptome studies performed in the target

Figure 3 Transcriptome studies performed in the target
Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 2 Shared genetic loci in systemic autoimmune diseases
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Tom Pettersson, M.D., Matti Klockars, M.D., Teddy Weber, M.D.

Tom Pettersson, M.D., Matti Klockars, M.D., Teddy Weber, M.D.
Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Main fields of interest.

Main fields of interest.
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,

(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,
Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,
Association of B cell TLR4 levels to disease activity.

Association of B cell TLR4 levels to disease activity.
Figure 1 Patterns of joint and organ involvement in rheumatic disease

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Similar presentations

Ads by Google